Table 1 Baseline patient characteristics of HFpEF progressor and non-progressor cohorts
From: Biomarker profiling for risk of future heart failure (HFpEF) development
Median [IQR] or N (%) | Total study cohort | HFpEF progressor | HFpEF Non progressor | p-value |
|---|---|---|---|---|
N | 90 | 30 | 60 | |
Age | 75.0 [69.1:78.2] | 76.0 [69.8:78.1] | 74.3 [68.8:78.2] | 0.4828 |
Male | 42 (46.7%) | 14 (46.7%) | 28 (46.7%) | > 0.99 |
BMI | 29.0 [25.0:34.5] | 33.0 [25.2:36.8] | 27.0 [25.0:30.0] | 0.0710 |
SBP | 137.5 [124.2:151.0] | 128.0 [111.2:144.5] | 140.5 [130.0:151.5] | 0.1181 |
DBP | 78.0 [70.2:84.0] | 73.5 [65.2:82.5] | 80.0 [75.8:86.0] | 0.0197 |
HDL | 1.2 [1.0:1.5] | 1.2 [1.0:1.5] | 1.2 [1.0:1.5] | 0.7979 |
Triglycerides | 1.6 [1.1:2.0] | 1.6 [1.1:2.0] | 1.5 [1.1:2.1] | 0.8742 |
RAAS | 69 (76.7%) | 24 (80.0%) | 45 (75.0%) | 0.7920 |
AA | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | - |
ARB | 38 (42.2%) | 14 (46.7%) | 24 (40.0%) | 0.7060 |
ACEI | 35 (38.9%) | 13 (43.3%) | 22 (36.7%) | 0.7020 |
Diuretic | 40 (44.4%) | 18 (60.0%) | 22 (36.7%) | 0.0610 |
BB | 48 (53.3%) | 19 (63.3%) | 29 (48.3%) | 0.2620 |
CCB | 45 (50.0%) | 17 (56.7%) | 28 (46.7%) | 0.5020 |
Anti-platelet | 59 (65.6%) | 22 (73.3%) | 37 (61.7%) | 0.3880 |
EF | 67.0 [62.0:72.8] | 66.0 [62.0:72.0] | 68.0 [62.0:73.0] | 0.4690 |
Lateral e’ | 7.1 [5.8:8.8] | 7.8 [6.2:10.5] | 6.5 [5.5:8.2] | 0.0298 |
Peak E | 73.0 [62.0:86.0] | 79.5 [69.8:95.0] | 69.0 [58.0:81.0] | 0.0016 |
E / lat. e’ | 10.4 [8.0:13.7] | 10.4 [8.2:12.7] | 10.6 [7.9:13.7] | 0.9477 |
LAVI | 33.0 [28.1:40.4] | 41.5 [29.4:48.2] | 31.5 [28.0:36.1] | 0.0029 |
LVMI | 102.4 [83.4:114.7] | 105.9 [102.2:126.0] | 97.4 [79.9:111.8] | 0.0284 |
LVDD* | 26 (34.7%) | 12 (46.2%) | 14 (28.6%) | 0.2050 |